A Dark Vector Cognition product

Item 1. Financial Statements

87K characters. Original on sec.gov ·

Item 1. Financial Statements

The 41 tables in Item 1. Financial Statements as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Financial Statements

Condensed Consolidated Statements of Earnings

(Unaudited)

Three Months Ended September 30,
(in millions, except per common share amounts)20222021
Revenue$49,603$43,968
Cost of products sold47,98942,326
Gross margin1,6141,642
Operating expenses:
Distribution, selling, general and administrative expenses1,1971,114
Restructuring and employee severance2918
Amortization and other acquisition-related costs7179
Impairments and (gain)/loss on disposal of assets, net153(2)
Litigation (recoveries)/charges, net2718
Operating earnings137415
Other (income)/expense, net2(4)
Interest expense, net2540
Loss on early extinguishment of debt—10
Earnings before income taxes110369
Provision for/(benefit from) income taxes(1)97
Net earnings111272
Less: Net earnings attributable to noncontrolling interests(1)(1)
Net earnings attributable to Cardinal Health, Inc.$110$271
Earnings per common share attributable to Cardinal Health, Inc.:
Basic$0.41$0.94
Diluted0.400.94
Weighted-average number of common shares outstanding:
Basic271287
Diluted273289
Cash dividends declared per common share$0.4957$0.4908

See notes to condensed consolidated financial statements.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q24
Financial Statements

Condensed Consolidated Statements of Comprehensive Income

(Unaudited)

Three Months Ended September 30,
(in millions)20222021
Net earnings$111$272
Other comprehensive loss:
Foreign currency translation adjustments and other(58)(25)
Net unrealized gain/(loss) on derivative instruments, net of tax(4)(2)
Total other comprehensive loss, net of tax(62)(27)
Total comprehensive income49245
Less: comprehensive income attributable to noncontrolling interests(1)(1)
Total comprehensive income attributable to Cardinal Health, Inc.$48$244

See notes to condensed consolidated financial statements.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q25
Financial Statements

Condensed Consolidated Balance Sheets

(in millions)September 30, 2022June 30, 2022
Assets(Unaudited)
Current assets:
Cash and equivalents$3,492$4,717
Trade receivables, net11,03910,561
Inventories, net15,89115,636
Prepaid expenses and other2,2742,021
Total current assets32,69632,935
Property and equipment, net2,3392,361
Goodwill and other intangibles, net7,3677,629
Other assets985953
Total assets$43,387$43,878
Liabilities and Shareholders’ Deficit
Current liabilities:
Accounts payable$28,362$27,128
Current portion of long-term obligations and other short-term borrowings578580
Other accrued liabilities2,6192,842
Total current liabilities31,55930,550
Long-term obligations, less current portion4,6894,735
Deferred income taxes and other liabilities8,9199,299
Shareholders’ deficit:
Preferred shares, without par value:
Authorized—500 thousand shares, Issued—none——
Common shares, without par value:
Authorized—755 million shares, Issued—327 million shares at September 30, 2022 and June 30,20222,5762,813
Accumulated deficit(301)(280)
Common shares in treasury, at cost: 65 million shares and 54 million shares at September 30, 2022 and June 30, 2022, respectively(3,880)(3,128)
Accumulated other comprehensive loss(176)(114)
Total Cardinal Health, Inc. shareholders' deficit(1,781)(709)
Noncontrolling interests13
Total shareholders’ deficit(1,780)(706)
Total liabilities and shareholders’ deficit$43,387$43,878

See notes to condensed consolidated financial statements.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q26
Financial Statements

Condensed Consolidated Statements of Shareholders' Equity/(Deficit)

(Unaudited)

Common SharesTreasury SharesAccumulated Other Comprehensive LossNoncontrolling InterestsTotal Shareholders’ Equity/(Deficit)
(in millions)Shares IssuedAmountRetained Earnings/(Accumulated Deficit)SharesAmount
Three Months Ended September 30, 2022
Balance at June 30, 2022327$2,813$(280)(54)$(3,128)$(114)$3$(706)
Net earnings1101111
Other comprehensive loss, net of tax(62)(62)
Purchase of noncontrolling interests(2)(2)
Employee stock plans activity, net of shares withheld for employee taxes—(37)14811
Share repurchase program activity(200)(12)(800)(1,000)
Dividends declared(131)(131)
Other(1)(1)
Balance at September 30, 2022327$2,576$(301)(65)$(3,880)$(176)$1$(1,780)
Three Months Ended September 30, 2021
Balance at June 30, 20213272,806$1,205(36)$(2,186)$(34)$3$1,794
Net earnings2711272
Other comprehensive loss, net of tax(27)(27)
Employee stock plans activity, net of shares withheld for employee taxes—(40)139(1)
Share repurchase program activity(100)(8)(400)(500)
Dividends declared(141)(141)
Other(1)(1)
Balance at September 30, 2021327$2,666$1,335(43)$(2,547)$(61)$3$1,396

See notes to condensed consolidated financial statements.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q27
Financial Statements

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Three Months Ended September 30,
(in millions)20222021
Cash flows from operating activities:
Net earnings$111$272
Adjustments to reconcile net earnings to net cash provided by/(used in) operating activities:
Depreciation and amortization171168
Impairments and (gain)/loss on disposal of assets, net153(2)
Loss on early extinguishment of debt—10
Share-based compensation2324
Provision for bad debts2912
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
Increase in trade receivables(508)(214)
Increase in inventories(264)(129)
Increase/(decrease) in accounts payable1,234(292)
Other accrued liabilities and operating items, net(926)(495)
Net cash provided by/(used in) operating activities23(646)
Cash flows from investing activities:
Proceeds from divestitures, net of cash sold—927
Additions to property and equipment(70)(67)
Proceeds from disposal of property and equipment2—
Purchases of investments(3)(2)
Proceeds from investments14
Net cash provided by/(used in) investing activities(70)862
Cash flows from financing activities:
Reduction of long-term obligations(7)(587)
Net tax withholdings from share-based compensation(14)(28)
Dividends on common shares(142)(149)
Purchase of treasury shares(1,000)(500)
Net cash used in financing activities(1,163)(1,264)
Effect of exchange rate changes on cash and equivalents(15)(5)
Cash reclassified from assets held for sale—109
Net decrease in cash and equivalents(1,225)(944)
Cash and equivalents at beginning of period4,7173,407
Cash and equivalents at end of period$3,492$2,463

See notes to condensed consolidated financial statements.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q28
Notes to Financial Statements

Notes to Condensed Consolidated Financial Statements

1. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.

References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (this "Form 10-Q") are to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise.

Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively.

Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts.

In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (the "2022 Form 10-K").

Recently Issued Financial Accounting Standards Not Yet Adopted

We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as

material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements.

Recently Adopted Financial Accounting Standards

There were no new material accounting standards adopted in the three months ended September 30, 2022.

2. Divestitures

In August 2021, we sold the Cordis business to Hellman & Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in Note 6. The Cordis business operated within our Medical segment.

3. Restructuring and Employee Severance

The following table summarizes restructuring and employee severance costs:

Three Months Ended September 30,
(in millions)20222021
Employee-related costs$19$8
Facility exit and other costs1010
Total restructuring and employee severance$29$18

Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of accelerated depreciation, costs associated with vacant facilities, professional, project management and other service fees to support divestitures, vendor transition fees, project consulting fees, and certain other divestiture-related costs.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q29
Notes to Financial Statements

During the three months ended September 30, 2022 and 2021, restructuring costs primarily related to the implementation of certain enterprise-wide cost-savings measures. During the three months ended September 30, 2021, restructuring also included costs related to the divestiture of the Cordis business.

The following table summarizes activity related to liabilities associated with restructuring and employee severance:

(in millions)Employee- Related CostsFacility Exit and Other CostsTotal
Balance at June 30, 2022$56$10$66
Additions20323
Payments and other adjustments(11)(10)(21)
Balance at September 30, 2022$65$3$68

4. Goodwill and Other Intangible Assets

Goodwill

The following table summarizes the changes in the carrying amount of goodwill by segment and in total:

(in millions)PharmaceuticalMedical (1)Total
Balance at June 30, 2022$2,673$3,182$5,855
Foreign currency translation adjustments and other—(26)(26)
Goodwill impairment—(154)(154)
Balance at September 30, 2022$2,673$3,002$5,675

(1)At September 30, 2022, the Medical segment accumulated goodwill impairment loss was $3.6 billion.

During the three months ended September 30, 2022, the Medical Unit continued to experience adverse financial results related to inflationary impacts and PPE demand and pricing. Due to the risks and uncertainties related to these impacts and an increase in the risk-free interest rate used in the discount rate, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit.

Our determination of the estimated fair value of the Medical Unit is based on a combination of the income-based approach (using a discount rate of 10.5 percent and a terminal growth rate of 2 percent), and market-based approaches. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. The carrying amount exceeded the fair value, which resulted in a pre-tax impairment charge of $154 million for the Medical Unit, which was recognized during the three months ended September 30, 2022 and is included in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings. This impairment charge was driven by an increase in the discount rate primarily due

to an increase in the risk-free interest rate. The carrying value of the Medical Unit at September 30, 2022 after recognizing the impairment charge was $6.7 billion, of which $1.8 billion was goodwill.

Other Intangible Assets

The following tables summarize other intangible assets by class at:

September 30, 2022
(in millions)Gross IntangibleAccumulated AmortizationNet IntangibleWeighted- Average Remaining Amortization Period (Years)
Indefinite-life intangibles:
Trademarks and patents$11$—$11N/A
Total indefinite-life intangibles11—11N/A
Definite-life intangibles:
Customer relationships3,2062,1571,04910
Trademarks, trade names and patents5463611858
Developed technology and other1,0375904479
Total definite-life intangibles4,7893,1081,6819
Total other intangible assets$4,800$3,108$1,692N/A
June 30, 2022
(in millions)Gross IntangibleAccumulated AmortizationNet Intangible
Indefinite-life intangibles:
Trademarks and patents$11$—$11
Total indefinite-life intangibles11—11
Definite-life intangibles:
Customer relationships3,2722,1651,107
Trademarks, trade names and patents552360192
Developed technology and other1,038574464
Total definite-life intangibles4,8623,0991,763
Total other intangible assets$4,873$3,099$1,774

Total amortization of intangible assets was $71 million and $78 million for the three months ended September 30, 2022 and 2021, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2023 through 2027 is as follows: $212 million, $258 million, $233 million, $206 million, and $174 million.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q30
Notes to Financial Statements

5. Long-Term Obligations and Other Short-Term Borrowings

Long-Term Debt

We had total long-term obligations, including the current portion and other short-term borrowings, of $5.3 billion at both September 30, 2022 and June 30, 2022. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $28.4 billion and $27.1 billion at September 30, 2022 and June 30, 2022, respectively.

During the three months ended September 30, 2021, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10 million loss on early extinguishment of debt. The early redemption was funded with available cash.

Other Financing Arrangements

In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. At September 30, 2022, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.

In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors.

Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1. At September 30, 2022, we were in compliance with this financial covenant.

6. Commitments, Contingent Liabilities and Litigation

Commitments

Generic Sourcing Venture with CVS Health Corporation ("CVS Health")

In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement.

Contingencies

New York Opioid Stewardship Act

In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.

The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. In October 2021, the U.S. Supreme Court declined to review the decision.

We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41 million for calendar years 2017 and 2018 during the fiscal year ended June 30, 2021 based on the probable estimated payment amount. In the second quarter of fiscal year 2022, we paid the State of New York $20 million, our portion of the assessment for calendar year 2017. As a result, at September 30, 2022, we had an accrual of $20 million, which reflects our best estimate of the portion of the assessment that we may owe for sales during calendar year 2018.

Legal Proceedings

We become involved from time to time in disputes, litigation and regulatory matters.

From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory

Cardinal Health | Q1 Fiscal 2023 Form 10-Q31
Notes to Financial Statements

agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.

From time to time, we become aware through employees, internal audits or other parties of possible product quality, regulatory or compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.

We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.

We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.

We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.

We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net, in our condensed consolidated statements of earnings; however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our

Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.

Opioid Lawsuits and Investigations

States & Political Subdivisions

National Settlement

As previously disclosed, in February 2022, we, along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and other political subdivisions. The Settlement Agreement became effective on April 2, 2022.

In addition to the Distributors, parties to the Settlement Agreement include 46 states, the District of Columbia and 5 U.S. territories. As of November 3, 2022, over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us had chosen to join the Settlement Agreement or have had their claims addressed by state legislation.

Under this Settlement Agreement, we will pay up to approximately $6.0 billion, the majority of which is expected to be paid over 18 years. The Settlement Agreement also includes injunctive relief terms related to distributors’ controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to engage in resolution discussions with certain non-participating political subdivisions and intend to defend ourselves vigorously against all remaining lawsuits.

Other Settlements

West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgment in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases.

In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $160 million to the State of Washington and its participating subdivisions and approximately $95 million to the

32Cardinal Health | Q1 Fiscal 2023 Form 10-Q
Notes to Financial Statements

State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. The terms of these agreements are consistent with the terms of the Settlement Agreement.

As of October 2022, a sufficient number of subdivisions in each state had agreed to join their respective agreement, and the court in each state ordered the cases to be dismissed. We are in the process of finalizing the consent judgments in each state, and each agreement will become effective upon the entry of the relevant consent judgment. When each of these agreements is finalized, Washington and Oklahoma will become subject to the Settlement Agreement and 48 of 49 states will then be subject to the Settlement Agreement.

We are engaged in resolution discussions with the Attorney General for the State of Alabama.

In January 2022, the Distributors entered into a term sheet with Native American tribes to resolve their opioid claims. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases.

During the three months ended September 30, 2022, we made our second annual payment of $372 million under the Settlement Agreement. In total, we have $6.03 billion accrued at September 30, 2022, of which $608 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.

Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing.

Department of Justice Investigations

We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations.

Private Plaintiffs

The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 454 lawsuits as of October, 2022. Of these, 151 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs.

A trial in a case involving 21 plaintiffs began in state court in Georgia in July 2022. A mistrial was declared shortly thereafter due to rising COVID-19 cases and a new trial date has been set for January 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results.

Insurance Litigation

We are involved in ongoing legal proceedings with insurers related their respective obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of September 30, 2022.

Cordis IVC Filter Matters

Product Liability Lawsuits

As of November 3, 2022, we are named as a defendant in 450 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,215 plaintiffs that allege personal injuries associated with the use of IVC filter products. Another 7 lawsuits involving similar claims by approximately 8 plaintiffs are pending in other jurisdictions. In August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits.

These lawsuits seek a variety of remedies, including unspecified monetary damages. In July 2021, we entered into an agreement to settle approximately 1,300 product liability claims. As a result, certain lawsuits have been dismissed and we expect additional lawsuits to be dismissed over the coming months. We continue to vigorously defend ourselves in the remaining lawsuits and are engaged in ongoing resolution discussions with certain plaintiffs.

At September 30, 2022, we had a total of $527 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.07 billion, net of estimated insurance

Cardinal Health | Q1 Fiscal 2023 Form 10-Q33
Notes to Financial Statements

recoveries. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained.

Shareholder Securities Litigation

In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In September 2021, the court denied our motion to dismiss. In September 2022, the court entered an order staying the case while the parties participate in mediation. We continue to vigorously defend ourselves against these claims.

Other Civil Litigation

Generic Pharmaceutical Pricing Antitrust Litigation

In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. The court granted our motion to dismiss, and the indirect purchasers filed an amended complaint. We intend to vigorously defend ourselves.

Active Pharmaceutical Ingredient Impurity Litigation

Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. We have been named as a defendant in an MDL alleging API impurities in certain generic blood pressure medications; however we no longer believe that these matters are material to us and we will no longer report on them.

Antitrust Litigation Proceeds

In October 2022, we received net cash proceeds resulting from the settlements of a lawsuit in which we were a class member or plaintiff of approximately $66 million, which will be recognized in litigation (recoveries)/charges, net, during the three months ending December 31, 2022.

7. Income Taxes

Fluctuations in our provision for/(benefit from) income taxes as a percentage of our pre-tax earnings (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items.

Tax Effects of Goodwill Impairment Charge

During the three months ended September 30, 2022, we recognized a $154 million pre-tax charge for goodwill impairment related to the Medical Unit. The net tax benefit related to this charge is $12 million for fiscal 2023.

Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings before income taxes for the year-to-date period to compute our benefit from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.

The tax effect of the goodwill impairment charge during the three months ended September 30, 2022 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairment in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to pre-tax earnings for three months ended September 30, 2022 resulted in recognizing an incremental interim tax benefit of approximately $22 million, which impacted the benefit from income taxes in the condensed consolidated statements of earnings during the three months ended September 30, 2022 and prepaid expenses and other assets in the condensed consolidated balance sheets at September 30, 2022. This interim tax benefit will reverse in future quarters of fiscal 2023.

Effective Tax Rate

During the three months ended September 30, 2022 and 2021, the effective tax rate was (0.7) percent and 26.3 percent, respectively. The effective tax rate for the three months ended September 30, 2022 reflects the impact of tax benefits from decreases in valuation allowances on net operating loss carryforwards and certain other discrete items.

Unrecognized Tax Benefits

We had $940 million and $943 million of unrecognized tax benefits at September 30, 2022 and June 30, 2022, respectively. Both the September 30, 2022 and June 30, 2022 balances include $858

34Cardinal Health | Q1 Fiscal 2023 Form 10-Q
Notes to Financial Statements

million of unrecognized tax benefits that, if recognized, would have an impact on the effective tax rate.

At September 30, 2022 and June 30, 2022, we had $49 million and $48 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings. These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.

It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of $75 million, exclusive of penalties and interest.

Other Tax Matters

We file income tax returns in the U.S. federal jurisdiction, various U.S. state and local jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2016 through the current fiscal year.

We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $77 million and $75 million at September 30, 2022 and June 30, 2022 respectively, and is included in other assets in the condensed consolidated balance sheets.

8. Fair Value Measurements

The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:

September 30, 2022
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$1,477$—$—$1,477
Other investments (1)88——88
Liabilities:
Forward contracts (2)—(5)—(5)
June 30, 2022
(in millions)Level 1Level 2Level 3Total
Assets:
Cash equivalents$2,425$—$—$2,425
Other investments (1)97——97
Forward contracts (2)—15—15

(1)The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.

(2) The fair value of interest rate swaps, foreign currency contracts and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.

9. Financial Instruments

We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.

Cardinal Health | Q1 Fiscal 2023 Form 10-Q35
Notes to Financial Statements

Interest Rate Risk Management

We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.

Currency Exchange Risk Management

We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.

Commodity Price Risk Management

We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.

Fair Value Hedges

We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings. For the three months ended September 30, 2022 and 2021, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.

During three months ended September 30, 2022 and 2021, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $100 million, respectively. These swaps were designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in our condensed consolidated balance sheets.

Cash Flow Hedges

We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.

Pre-tax gains recognized in other comprehensive loss were $4 million for the three months ended September 30, 2022. Pre-tax gains recognized in other comprehensive loss were immaterial for the three months ended September 30, 2021. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three months ended September 30, 2022 and 2021. All gains and losses currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.

Net Investment Hedges

We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.

Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.

Pre-tax gains from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss were $22 million and a $5 million for the three months ended September 30, 2022 and 2021, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4 million and $6 million during the three months ended September 30, 2022 and 2021, respectively.

36Cardinal Health | Q1 Fiscal 2023 Form 10-Q
Notes to Financial Statements

Economic (Non-Designated) Hedges

We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $6 million loss and an immaterial gain during the three months ended September 30, 2022 and 2021, respectively. The principal currencies managed through foreign currency contracts are the Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht.

Fair Value of Financial Instruments

The carrying amounts of cash and equivalents, trade receivables, accounts payable, and other accrued liabilities at September 30, 2022 and June 30, 2022 approximate fair value due to their short-term maturities.

The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:

(in millions)September 30, 2022June 30, 2022
Estimated fair value$4,838$5,049
Carrying amount5,2675,315

The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.

10. Shareholders' Equity/(Deficit)

During the three months ended September 30, 2022, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program is expected to conclude in the second quarter of fiscal 2023.

During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0 million common shares.

We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.

Accumulated Other Comprehensive Loss

The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total:

(in millions)Foreign Currency Translation AdjustmentsUnrealized Gain/(Loss) on Derivatives, net of taxAccumulated Other Comprehensive Loss
Balance at June 30, 2022$(102)$(12)$(114)
Other comprehensive loss, before reclassifications(58)(2)(60)
Amounts reclassified to earnings—(2)(2)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax expense of $7 million(58)(4)(62)
Balance at September 30, 2022$(160)$(16)$(176)
(in millions)Foreign Currency Translation AdjustmentsUnrealized Gain/(Loss) on Derivatives, net of taxAccumulated Other Comprehensive Loss
Balance at June 30, 2021$(46)$12$(34)
Other comprehensive loss, before reclassifications(25)(1)(26)
Amounts reclassified to earnings—(1)(1)
Total other comprehensive loss attributable to Cardinal Health, Inc., net of tax(25)(2)(27)
Balance at September 30, 2021$(71)$10$(61)

11. Earnings Per Share Attributable to Cardinal Health, Inc.

The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:

Three Months Ended September 30,
(in millions)20222021
Weighted-average common shares–basic271287
Effect of dilutive securities:
Employee stock options, restricted share units, and performance share units22
Weighted-average common shares–diluted273289

The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive for both

Cardinal Health | Q1 Fiscal 2023 Form 10-Q37
Notes to Financial Statements

the three months ended September 30, 2022 and 2021 were 4 million.

12. Segment Information

Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.

Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products.

Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.

Revenue

The following table presents revenue for each reportable segment, disaggregated revenue within our two reportable segments and Corporate:

Three Months Ended September 30,
(in millions)20222021
Pharmaceutical Distribution and Specialty Solutions (1) (2)$45,547$39,614
Nuclear and Precision Health Solutions (3)281208
Pharmaceutical segment revenue45,82839,822
Medical distribution and products (4)3,1403,567
Cardinal Health at-Home Solutions638582
Medical segment revenue3,7784,149
Total segment revenue49,60643,971
Corporate (5)(3)(3)
Total revenue$49,603$43,968

(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services".

(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.

(3)Increase from prior year primarily relates to new product launches and, to a lesser extent, the impact of a change in revenue recognition presentation from agent to principal for certain customer contracts.

(4)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.

(5)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

The following table presents revenue by geographic area:

Three Months Ended September 30,
(in millions)20222021
United States$48,477$42,841
International1,1291,130
Total segment revenue49,60643,971
Corporate (1)(3)(3)
Total revenue$49,603$43,968

(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Cardinal Health | Q1 Fiscal 2020 Form 10-Q38
Notes to Financial Statements

Segment Profit

We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.

We do not allocate the following items to our segments:

  • last-in first-out, or ("LIFO"), inventory charges/(credits);

  • surgical gown recall costs/(income);

  • shareholder cooperation agreement costs;

  • state opioid assessment related to prior fiscal years;

  • restructuring and employee severance;

  • amortization and other acquisition-related costs;

  • impairments and (gain)/loss on disposal of assets, net;

  • litigation (recoveries)/charges, net;

  • other (income)/expense, net;

  • interest expense, net;

  • loss on early extinguishment of debt;

  • (gain)/loss on sale of equity interest in naviHealth; or

  • provision for/(benefit from) income taxes

In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $6 million and $7 million for the three months ended September 30, 2022 and 2021, respectively.

The following table presents segment profit by reportable segment and Corporate:

Three Months Ended September 30,
(in millions)20222021
Pharmaceutical$431$406
Medical(8)123
Total segment profit423529
Corporate(286)(114)
Total operating earnings$137$415

The following table presents total assets for each reportable segment and Corporate at:

(in millions)September 30, 2022June 30, 2022
Pharmaceutical$27,253$26,409
Medical11,33811,632
Corporate4,7965,837
Total assets$43,387$43,878

13. Share-Based Compensation

We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees.

The following table provides total share-based compensation expense by type of award:

Three Months Ended September 30,
(in millions)20222021
Restricted share unit expense$17$18
Performance share unit expense66
Total share-based compensation$23$24

The total tax benefit related to share-based compensation was $3 million and $4 million for the three months ended September 30, 2022 and 2021, respectively.

Restricted Share Units

Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.

The following table summarizes all transactions related to restricted share units under the Plans:

(in millions, except per share amounts)Restricted Share UnitsWeighted-Average Grant Date Fair Value per Share
Nonvested at June 30, 20222.7$46.03
Granted1.269.95
Vested(1.2)49.62
Canceled and forfeited(0.2)54.94
Nonvested at September 30, 20222.5$59.43

At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $119 million, which is expected to be recognized over a weighted-average period of two years.

Performance Share Units

Performance share units vest over a three-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount for the fiscal 2020 and 2021 grants and zero to 234 percent for the fiscal 2022 and 2023 grants. Performance share

Cardinal Health | Q1 Fiscal 2023 Form 10-Q39
Notes to Financial Statements

units accrue cash dividend equivalents that are payable upon vesting of the awards.

The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):

(in millions, except per share amounts)Performance Share UnitsWeighted-Average Grant Date Fair Value per Share
Nonvested at June 30, 20221.2$54.32
Granted0.376.79
Vested(0.4)59.04
Canceled and forfeited(0.2)57.50
Nonvested at September 30, 20220.9$72.01

At September 30, 2022, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $28 million, which is expected to be recognized over a weighted-average period of two years if the performance goals are achieved.

40Cardinal Health | Q1 Fiscal 2023 Form 10-Q

Previous: Item 1A. Risk Factors · Next: Item 6. Exhibits